Mirtazapine and Shortness of Breath
Mirtazapine does not directly cause shortness of breath as a primary adverse effect, but dyspnea has been reported in post-marketing surveillance and clinical trials, occurring in approximately 1% of patients. 1
Understanding the Evidence
Direct Respiratory Effects
The FDA drug label for mirtazapine lists dyspnea (shortness of breath) as an adverse reaction that occurred in clinical trials, though it was uncommon (1% of patients in controlled studies) 1. This is important context: while mirtazapine itself is not a respiratory depressant like opioids, some patients do experience breathlessness while taking it.
Importantly, mirtazapine has been shown to be safe in cardiovascular disease patients, including those with heart failure who may already experience dyspnea 2. The 2024 American Heart Association guidelines specifically note that mirtazapine "has been shown to be safe" in patients with cardiovascular disease, though they acknowledge its efficacy for depression in this population hasn't been fully assessed 2.
The Breathlessness Treatment Paradox
Interestingly, mirtazapine has been investigated as a treatment for chronic breathlessness in advanced lung disease. However, a large 2024 phase 3 trial (BETTER-B) definitively showed that mirtazapine does NOT improve severe breathlessness in patients with COPD or interstitial lung disease and may actually cause adverse reactions 3. This trial enrolled 225 patients and found no benefit at doses of 15-45 mg daily over 56 days, with 64% of mirtazapine-treated patients experiencing adverse reactions versus 40% on placebo 3.
Clinical Management Approach
When Dyspnea Occurs on Mirtazapine:
Assess timing and severity: Determine if dyspnea began after starting mirtazapine or represents worsening of pre-existing breathlessness
Rule out serious cardiac complications:
- Check for QT prolongation, as mirtazapine can prolong QTc interval 1
- Post-marketing reports include cases of Torsades de Pointes and ventricular tachycardia, particularly with overdose or in patients with other QT-prolonging risk factors 1
- Monitor ECG if patient has cardiovascular disease, family history of QT prolongation, or takes other QTc-prolonging medications 1
Consider Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS):
Evaluate for weight gain and fluid retention:
Check for serotonin syndrome (though respiratory symptoms are not primary):
- Particularly if patient takes other serotonergic drugs 1
- Look for autonomic instability, mental status changes, neuromuscular symptoms
Management Steps:
If dyspnea is mild and tolerable:
- Continue mirtazapine if therapeutic benefit outweighs this side effect
- Monitor closely for worsening
- Ensure optimal management of any underlying cardiopulmonary disease
If dyspnea is moderate to severe or concerning:
- Discontinue mirtazapine and observe for resolution
- Consider alternative antidepressants: SSRIs (particularly sertraline, which has lower QTc risk) are well-studied and safe in cardiovascular disease 2
- If sedation/sleep benefits were important, consider trazodone as alternative 2
Important Caveats
- Do not use mirtazapine to treat breathlessness itself - the BETTER-B trial definitively showed it doesn't work and may cause harm 3
- The majority of serious adverse events with mirtazapine (including cardiac complications) occur with overdose or in patients with multiple risk factors 1
- Mirtazapine's safety profile in cardiovascular disease is generally favorable, but individual monitoring remains essential 2
- Agranulocytosis, though rare (2/2796 patients in trials), can present with respiratory infections and should be considered if dyspnea accompanies fever and sore throat 1